Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal

Impact · against what's priced in

Bausch + Lomb gains long-term optionality from positive Phase Ib pain data and a move to Phase III for its dry eye treatment, though the latter carries higher risk due to a failed primary endpoint. Because these programs will not launch within the three-year plan, the near-term financial impact is negligible.

BLCO+0.30: No priced-in read yet

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal

What matters in this story

1 Reason Compass Pathways Is Worth a Second Look This Month

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal

What matters in this story

1 Reason Compass Pathways Is Worth a Second Look This Month

How each ticker is affected

Track these names every morning.

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

Tiziana's experimental MS treatment meets main goals in mid-stage study

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal

What matters in this story

Next reads from the same story arc

1 Reason Compass Pathways Is Worth a Second Look This Month

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal

What matters in this story

Next reads from the same story arc

1 Reason Compass Pathways Is Worth a Second Look This Month

How each ticker is affected

Track these names every morning.

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

Tiziana's experimental MS treatment meets main goals in mid-stage study

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing